Inhibition of Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2) is Protective in Pulmonary Hypertension

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling

(2019) Zhiyu Dai et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Intranasal MMI-0100 Attenuates Aβ1−42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway

(2019) JinHong Jiang et al.   Frontiers in Immunology

Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension

(2018) Olivier Boucherat et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Protecting the heart through MK2 modulation, toward a role in diabetic cardiomyopathy and lipid metabolism

(2018) Matthieu Ruiz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research

(2018) Steeve Provencher et al.   CIRCULATION RESEARCH

MK2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis

(2018) Jiurong Liang et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

(2018) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis

(2018) Anna Reustle et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth

(2017) Anita L. Ray et al.   INTERNATIONAL JOURNAL OF CANCER

Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/β-Catenin Signaling in Hypertension

(2017) Shahnawaz Ali Bhat et al.   MOLECULAR NEUROBIOLOGY

Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases

(2017) Rakesh Kumar Singh et al.   Pharmacological Reports

Inhibition of fatty acid synthase is protective in pulmonary hypertension

(2016) Neetu Singh et al.   BRITISH JOURNAL OF PHARMACOLOGY

Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP)

(2016) Doan Duy Hai Tran et al.   CELLULAR SIGNALLING

Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension

(2016) Guo-Kun Wang et al.   Oncotarget

Upregulated miR-17 Regulates Hypoxia-Mediated Human Pulmonary Artery Smooth Muscle Cell Proliferation and Apoptosis by Targeting Mitofusin 2

(2016) Zheng Lu et al.   MEDICAL SCIENCE MONITOR

The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension

(2015) Alistair C. Church et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Right Ventricular Adaptation and Failure in Pulmonary Arterial Hypertension

(2015) John J. Ryan et al.   CANADIAN JOURNAL OF CARDIOLOGY

Emerging translational approaches to target STAT3 signalling and its impact on vascular disease

(2015) Jochen Dutzmann et al.   CARDIOVASCULAR RESEARCH

Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches

(2015) Kyoung-Ha Park et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Poly (ADP-ribose) polymerase-1: An emerging target in right ventricle dysfunction associated with pulmonary hypertension

(2015) Gurpreet Kaur et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition

(2014) Lei Xu et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury

(2014) Piyushkumar Kapopara et al.   THROMBOSIS AND HAEMOSTASIS

Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice

(2013) Jason M. Aliotta et al.   CARDIOVASCULAR RESEARCH

The mitochondrial permeability transition pore: a mystery solved?

(2013) Paolo Bernardi   Frontiers in Physiology

Immune and inflammatory mechanisms in pulmonary arterial hypertension

(2012) Hala El Chami et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation Is Controlled by Forkhead Box M1

(2011) Aarti Raghavan et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Cell-penetrating peptides can confer biological function: Regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides

(2011) Jamie L. Brugnano et al.   JOURNAL OF CONTROLLED RELEASE

Mechanisms of disease: pulmonary arterial hypertension

(2011) Ralph T. Schermuly et al.   Nature Reviews Cardiology

Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo

(2011) Akihito Muto et al.   VASCULAR PHARMACOLOGY

Overview of Current Therapeutic Approaches for Pulmonary Hypertension

(2011) Jason A. Stamm et al.   Pulmonary Circulation

Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Angiotensin II–Induced Inflammation and Hypertension

(2010) Talin Ebrahimian et al.   HYPERTENSION

Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce

(2009) Brian Ward et al.   JOURNAL OF PEPTIDE SCIENCE

MK2: a novel molecular target for anti-inflammatory therapy

(2008) Senthil Duraisamy et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension

(2008) Stéphanie Sauvageau et al.   PEPTIDES